Biomerica (NASDAQ:BMRA – Get Free Report) and Ainos (NASDAQ:AIMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Analyst Recommendations
This is a summary of current ratings and price targets for Biomerica and Ainos, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Ainos | 1 | 0 | 0 | 0 | 1.00 |
Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 423.26%. Given Biomerica’s higher probable upside, analysts plainly believe Biomerica is more favorable than Ainos.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $5.31 million | 1.00 | -$4.97 million | ($0.89) | -1.93 |
| Ainos | $120,000.00 | 132.49 | -$14.77 million | ($2.89) | -0.65 |
Biomerica has higher revenue and earnings than Ainos. Biomerica is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
22.3% of Biomerica shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Biomerica and Ainos’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -96.49% | -98.14% | -70.42% |
| Ainos | -11,912.10% | -160.55% | -62.29% |
Risk & Volatility
Biomerica has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500.
Summary
Biomerica beats Ainos on 8 of the 12 factors compared between the two stocks.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
About Ainos
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
